Navigation Links
Derma Sciences Announces Commercial Launch of XTRASORB(TM)
Date:10/21/2008

Novel polymer-based super-absorbent dressing will be first of its kind in

US and Canada

PRINCETON, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a company specializing in advanced wound care, today announced the commercial launch of its newest product -- XTRASORB(TM) Super Absorbent Dressing. The novel dressing features a polymer-based core that could help change the way clinicians manage heavily exuding wounds, currently a significant issue in wound care. The dressing will be launched at next week's Clinical Symposium on Advances in Skin & Wound Care in Las Vegas.

Commenting on the launch, CEO Ed Quilty stated, "This is something we have been excited about for quite a while. Foam dressings, for highly exuding wounds, is the single largest category of moist wound dressings, with over $300 million in global sales. Still, even the best dressings in this category have limitations. Clinicians still want dressings to hold more fluid to reduce the number of time-consuming and costly dressing changes. Additionally, the fluid that a foam dressing does absorb is at a high risk of being pushed back onto the wound bed, potentially causing serious complications to the wound. For these reasons, our market research shows that clinicians will love the fact that XTRASORB can absorb roughly 50% more than even the most absorbent foam dressing, and that the polymer-based super-absorbent core forms a gel which locks all the wound fluid inside the dressing and away from the wound. This has multiple benefits, including reducing the risk of wound breakdown due to excessive moisture, as well as keeping harmful bacteria often found in wound fluid away from the wound."

Quilty continued, "Based on our research and feedback from customers, we are extremely confident that we will have another successful product launch. We launched MEDIHONEY(R) Dressings last year at the Clinical Symposium, and we have done very well with that product. Our expectations for XTRASORB are very high, and we look forward to it being a significant contributor to our overall growth moving forward. This is yet another step in the course we've charted out over the past several years -- using the cash flow from our $50+ million revenue baseline business to fund the development of novel higher margin advanced wound care products, and then to launch and support them with marketing and our growing sales organization. This is what is going to drive our topline growth and profitability."

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in Q3 of 2008. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

Contact: Derma Sciences, Inc. Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO r.barrio@allencaron.com

equilty@dermasciences.com

(609) 514-4744 Brian Kennedy (media)

brian@allencaron.com

(212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
2. Age Spots Are No Match for Cosmetic Dermatology Treatments
3. Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U.S. Open
4. Watson Announces Limited Recall of Fentanyl Transdermal System
5. Derma Sciences Conference Call Advisory
6. American Academy of Dermatology: Dermatologists Warn Ceramic Flat Irons Could Damage Hair and Lead to Hair Breakage
7. American Academy of Dermatology: Acne and Rosacea Got You Seeing Red? Patients with Skin of Color Advised to Seek Proper Diagnosis, Treatment to Prevent Common Side Effects
8. Galderma announces approval for Differin gel 0.1 percent in Japan
9. Dermatologists In Denial: Controversial New Chocolate Nutraceutical Claims to be Good for Your Skin
10. 4th Annual Dermatology Nurses Association Summer Meeting to Arrive in Windy City
11. Derma Sciences Launches Two New MEDIHONEY(TM) Formulations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... VA (PRWEB) , ... May 26, 2017 , ... ... pleased to announce a new educational seminar to focus on current legislative activity ... News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will continue ...
(Date:5/26/2017)... Nevada (PRWEB) , ... May 26, 2017 , ... ... produce the first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed ... conference applications. “We are thrilled to partner with Cupron® to provide customers ...
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and helps ... series is on hiking in American. Viewers can reconnect with America as it explores ... hiking. , Many consumers have looked for an inventive new place for a family ...
(Date:5/26/2017)... ... ... of Eden”: retells the stories of three Bible figures in modern terms. “Just What ... trader, horse farmer, artist and a former GM journeyman. Born in 1953 in Portland, ... to Dayton, Ohio, where Penny graduated high school. At sixteen, she toured France to ...
(Date:5/24/2017)... New York, New York (PRWEB) , ... May 24, 2017 , ... ... and general vascular surgery in New York City. He is known for ... his broad specialization in vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... SAN DIEGO , May 4, 2017 ... 2017 Annual Clinical and Scientific Meeting— OBP Medical , ... devices, today announced the launch of a new extra-small ... and ER-SPEC vaginal specula. Already available ... and extra-large sizes makes OBP Medical,s line of single-use ...
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
(Date:5/3/2017)... , May 3, 2017 A Catheterization ... hospital or healthcare facility. Commonly referred to as ... equipped with diagnostic imaging technology to give physicians ... heart. In these spaces, a team of physicians ... angioplasty, percutaneous coronary intervention, congenital heart defect closure, ...
Breaking Medicine Technology: